Acusphere Inc. Earnings Conference Call (Q1 2008)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other May 8 Calls Today's Calls

Call Details Acusphere Inc. Earnings Conference Call (Q1 2008) Thu, May 8, 2008, 4:30 pm Eastern Listen to the archived event audio About Acusphere Inc. (NasdaqGM:ACUS) Acusphere, Inc., a specialty pharmaceutical company, develops new drugs and formulations of existing drugs using its proprietary porous microparticle technology in the United States. Its porous microparticle technology enables to control the size and porosity of particles, including nanoparticles and microparticles. The company develops products in the areas of cardiology, oncology, and asthma. Its lead product candidate Imagify, a cardiovascular drug is in Phase III clinical development for the detection of coronary artery disease. The company’s products also include AI-850, a Phase I clinical trial completed product candidate that utilizes hydrophobic drug delivery system to improve the dissolution rate of a cancer drug; and AI-128, a Phase I clinical study completed formulation of asthma drug, which utilizes pulmonary drug delivery system. Acusphere has a license agreement with Cephalon, Inc. to provide license to Acusphere’s Hydrophobic Drug Delivery System for oncology applications, along with the rights to AI-850, Acusphere’s formulation of paclitaxel. The company was founded in 1993 and is headquartered in Watertown, Massachusetts. More Info: Quote | Chart | News | Profile | Reports | Research | Msgs | Insider | Financials | Analyst Ratings